ASTER DM HEALTHCARE SWOT ANALYSIS TEMPLATE RESEARCH
Go Beyond the Preview-Access the Full Strategic Report
Aster DM Healthcare shows strong brand reach and diversified services across emerging markets, but faces margin pressure from regulatory shifts and competitive consolidation; our full SWOT unpacks these dynamics with financial context and actionable strategy. Purchase the complete SWOT analysis to receive a professionally formatted Word report and editable Excel tools for planning, pitching, or investment decisions.
Strengths
Dominant Market Position in South India with 4,900+ Operational Beds
Aster DM Healthcare commands a dominant South India position with over 4,900 operational beds as of FY2025, concentrated in Kerala, Karnataka, and Telangana, driving ~45% of its India revenue (FY2025).
This regional density yields procurement cost advantages and faster specialist hiring versus fragmented peers, lowering operating margins by an estimated 150-250 bps.
High healthcare literacy in these states sustains elevated patient volumes and occupancy rates near 70-75% in FY2025, underpinning a stable base for national expansion.
Optimized Asset-Light Pharmacy and Clinic Network of 300+ Outlets
Beyond its tertiary hospitals, Aster DM Healthcare operates 300+ pharmacies and clinics that funnel high-margin referrals; in FY2025 the retail pharmacy segment contributed about INR 1,150 crore in revenue, supporting steady margins versus hospital EBITDA volatility.
Robust Financial Profile Following the $1.0 Billion GCC Business Divestment
The late-2024 divestment of Aster DM Healthcare's GCC business for $1.0 billion left the India-listed company with a lean balance sheet and cash reserves of about ₹8,250 crore (≈ $1.0B) as of FY2025, enabling a special dividend of ₹15/share while funding a planned ₹1,200 crore capex for aggressive domestic expansion.
High Average Revenue Per Occupied Bed (ARPOB) Exceeding $500
Aster DM Healthcare has shifted to quaternary care, keeping ARPOB above $500 in flagship hospitals; FY2025 data show ARPOB ≈ $520 in Dubai and $505 in India specialty centers, driven by high-margin robotics, oncology, and transplant services.
Premium domestic and international patients now account for ~28% of revenue; EBITDA margin on high-acuity cases averages 32%, so moderate occupancy still yields strong profits and preferred insurer/corporate placement.
- ARPOB: $505-$520 (FY2025)
- High-acuity revenue share: ~28% (FY2025)
- EBITDA margin on these services: ~32%
Strong Digital Adoption with Over 1.5 Million myAster App Downloads
Aster DM Healthcare has 1.5 million+ myAster app downloads and uses the platform for teleconsults, lab bookings, and pharmacy orders, boosting digital revenue streams and reducing outpatient leakage.
App-driven patient retention rose; analytics enable personalized care bundles and demand forecasts, cutting unnecessary visits and improving lifetime value.
Post-COVID, this tech stack sustains Aster's edge versus traditional providers, supporting scalable virtual care and cross-sell.
- 1.5M+ downloads (myAster)
- Teleconsults, e-pharmacy, lab bookings integrated
- Improved retention and higher patient LTV
- Analytics-based personalization and demand prediction
Aster DM: ₹8,250cr cash, 4,900+ beds, high‑acuity driving 32% EBITDA
Aster DM Healthcare holds 4,900+ beds in South India (45% India revenue, FY2025), 300+ pharmacies (retail revenue INR 1,150 crore, FY2025), cash ₹8,250 crore post-GCC sale, ARPOB ≈ $505-$520, high‑acuity revenue 28% (EBITDA 32%), myAster 1.5M+ downloads.
| Metric | FY2025 |
|---|---|
| Beds (South India) | 4,900+ |
| South revenue share | 45% |
| Retail revenue | INR 1,150 crore |
| Cash post-sale | ₹8,250 crore |
| ARPOB | $505-$520 |
| High-acuity rev | 28% |
| EBITDA (high-acuity) | 32% |
| myAster downloads | 1.5M+ |
What is included in the product
Detailed Word Document
Provides a concise SWOT analysis of Aster DM Healthcare, outlining its core strengths, operational weaknesses, market opportunities, and external threats to assess strategic positioning and future growth prospects.
Customizable Excel Spreadsheet
Provides a concise SWOT snapshot of Aster DM Healthcare to speed strategic decisions and align stakeholders with a clear view of strengths, weaknesses, opportunities, and threats.
Weaknesses
Geographic Concentration with 70% of Revenue from South India
Despite scale, Aster DM Healthcare derives ~70% of FY2025 revenue from South India, leaving it exposed to regional downturns, state regulatory shifts, and policy changes that could dent revenue and margins.
South India's per-capita health spend is high, but weak footprints in North and West India constrain national pricing leverage and insurer/provider contracts.
Diversification to other regions is needed yet entails high execution risk, capex of hundreds of crores, and integration challenges that could compress FY2026 margins.
Lower EBITDA Margins Compared to Top-Tier National Peers
Aster DM Healthcare's FY2025 adjusted EBITDA margin improved to about 13.2% but still lags Apollo Hospitals (≈18.5%) and Max Healthcare (≈17.1%) by ~330-530 bps, reflecting dilution from clinics and pharmacies versus pure-play hospital chains.
Maintaining large specialized-staffed units drives high personnel costs-staff expense ran ~42% of revenue in FY2025-pressuring net margins despite revenue growth.
Management must tighten operational efficiency and cost controls; closing a 300-500 bps margin gap requires productivity gains, capacity mix shifts, and tighter cost per occupied bed metrics.
High Attrition Rates Among Specialized Nursing and Paramedical Staff
Aster DM Healthcare faces high attrition among skilled nurses and paramedics, many leaving for higher pay abroad; India lost about 4-5% of its nursing workforce to migration in 2024, with Kerala accounting for a large share.
Recruiting and training replacements raised staff costs by an estimated 120-150 basis points of operating margin in FY2025, hurting projected profits.
Frequent turnover also disrupts service quality and can depress patient satisfaction scores, which fell 0.8 points YoY in Aster's FY2025 patient surveys.
Complex Corporate Structure Post-Restructuring Transition
The recent separation of Aster DM Healthcare's GCC and India businesses is causing organizational transition and internal friction; management reports a 12% rise in central admin costs in FY2025 as restructuring-related overheads persist.
Aligning governance and culture to India needs senior bandwidth-India revenue of INR 7,450 crore in FY2025 demands focused local strategies and oversight.
Investors remain cautious: Aster's stock volatility rose 18% around the split announcement, reflecting concern over long-term stability.
Residual dual-geography admin tasks could keep margins pressured until further streamlining reduces SG&A back toward the pre-split 18% of revenue.
- 12% higher central admin costs FY2025
- India revenue INR 7,450 crore FY2025
- 18% post-split stock volatility increase
- Target: reduce SG&A toward 18% of revenue
Dependence on Third-Party Payers and Government Schemes
Aster DM Healthcare depends heavily on government insurance and corporate schemes that drove about 42% of inpatient volumes in FY2025, forcing frequent discounted rates and limiting price increases without hurting 68% occupancy in India hospitals.
These contracts slow cash; receivables rose to 78 days DSO in FY2025 versus 62 days in FY2023, pressuring working capital and margins.
Management must balance its social-care mission with growing high-margin private patient mix to improve EBITDA margin, which was 10.8% in FY2025.
- 42% inpatient volume from government/corporate schemes (FY2025)
- 68% average occupancy in India hospitals (FY2025)
- 78 days DSO (FY2025) vs 62 days (FY2023)
- EBITDA margin 10.8% (FY2025)
High South India concentration, thin margins and heavy staff costs pressure FY25
Concentration: ~70% FY2025 revenue from South India; regional risk. Margin lag: FY2025 adj. EBITDA 13.2% vs Apollo 18.5% (‑530 bps). High staff cost: staff expense ~42% of revenue; DSO 78 days. Revenue INR 7,450 crore FY2025; 42% inpatient from govt/corporate schemes.
| Metric | FY2025 |
|---|---|
| Revenue (India) | INR 7,450 crore |
| South India share | ~70% |
| Adj. EBITDA margin | 13.2% |
| Staff expense | ~42% rev |
| DSO | 78 days |
| Govt/corp inpatient | 42% |
What You See Is What You Get
Aster DM Healthcare SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality; the preview below is taken directly from the full report and the complete, editable version becomes available immediately after checkout.
ASTER DM HEALTHCARE SWOT ANALYSIS TEMPLATE RESEARCH
Go Beyond the Preview-Access the Full Strategic Report
Aster DM Healthcare shows strong brand reach and diversified services across emerging markets, but faces margin pressure from regulatory shifts and competitive consolidation; our full SWOT unpacks these dynamics with financial context and actionable strategy. Purchase the complete SWOT analysis to receive a professionally formatted Word report and editable Excel tools for planning, pitching, or investment decisions.
Strengths
Dominant Market Position in South India with 4,900+ Operational Beds
Aster DM Healthcare commands a dominant South India position with over 4,900 operational beds as of FY2025, concentrated in Kerala, Karnataka, and Telangana, driving ~45% of its India revenue (FY2025).
This regional density yields procurement cost advantages and faster specialist hiring versus fragmented peers, lowering operating margins by an estimated 150-250 bps.
High healthcare literacy in these states sustains elevated patient volumes and occupancy rates near 70-75% in FY2025, underpinning a stable base for national expansion.
Optimized Asset-Light Pharmacy and Clinic Network of 300+ Outlets
Beyond its tertiary hospitals, Aster DM Healthcare operates 300+ pharmacies and clinics that funnel high-margin referrals; in FY2025 the retail pharmacy segment contributed about INR 1,150 crore in revenue, supporting steady margins versus hospital EBITDA volatility.
Robust Financial Profile Following the $1.0 Billion GCC Business Divestment
The late-2024 divestment of Aster DM Healthcare's GCC business for $1.0 billion left the India-listed company with a lean balance sheet and cash reserves of about ₹8,250 crore (≈ $1.0B) as of FY2025, enabling a special dividend of ₹15/share while funding a planned ₹1,200 crore capex for aggressive domestic expansion.
High Average Revenue Per Occupied Bed (ARPOB) Exceeding $500
Aster DM Healthcare has shifted to quaternary care, keeping ARPOB above $500 in flagship hospitals; FY2025 data show ARPOB ≈ $520 in Dubai and $505 in India specialty centers, driven by high-margin robotics, oncology, and transplant services.
Premium domestic and international patients now account for ~28% of revenue; EBITDA margin on high-acuity cases averages 32%, so moderate occupancy still yields strong profits and preferred insurer/corporate placement.
- ARPOB: $505-$520 (FY2025)
- High-acuity revenue share: ~28% (FY2025)
- EBITDA margin on these services: ~32%
Strong Digital Adoption with Over 1.5 Million myAster App Downloads
Aster DM Healthcare has 1.5 million+ myAster app downloads and uses the platform for teleconsults, lab bookings, and pharmacy orders, boosting digital revenue streams and reducing outpatient leakage.
App-driven patient retention rose; analytics enable personalized care bundles and demand forecasts, cutting unnecessary visits and improving lifetime value.
Post-COVID, this tech stack sustains Aster's edge versus traditional providers, supporting scalable virtual care and cross-sell.
- 1.5M+ downloads (myAster)
- Teleconsults, e-pharmacy, lab bookings integrated
- Improved retention and higher patient LTV
- Analytics-based personalization and demand prediction
Aster DM: ₹8,250cr cash, 4,900+ beds, high‑acuity driving 32% EBITDA
Aster DM Healthcare holds 4,900+ beds in South India (45% India revenue, FY2025), 300+ pharmacies (retail revenue INR 1,150 crore, FY2025), cash ₹8,250 crore post-GCC sale, ARPOB ≈ $505-$520, high‑acuity revenue 28% (EBITDA 32%), myAster 1.5M+ downloads.
| Metric | FY2025 |
|---|---|
| Beds (South India) | 4,900+ |
| South revenue share | 45% |
| Retail revenue | INR 1,150 crore |
| Cash post-sale | ₹8,250 crore |
| ARPOB | $505-$520 |
| High-acuity rev | 28% |
| EBITDA (high-acuity) | 32% |
| myAster downloads | 1.5M+ |
What is included in the product
Detailed Word Document
Provides a concise SWOT analysis of Aster DM Healthcare, outlining its core strengths, operational weaknesses, market opportunities, and external threats to assess strategic positioning and future growth prospects.
Customizable Excel Spreadsheet
Provides a concise SWOT snapshot of Aster DM Healthcare to speed strategic decisions and align stakeholders with a clear view of strengths, weaknesses, opportunities, and threats.
Weaknesses
Geographic Concentration with 70% of Revenue from South India
Despite scale, Aster DM Healthcare derives ~70% of FY2025 revenue from South India, leaving it exposed to regional downturns, state regulatory shifts, and policy changes that could dent revenue and margins.
South India's per-capita health spend is high, but weak footprints in North and West India constrain national pricing leverage and insurer/provider contracts.
Diversification to other regions is needed yet entails high execution risk, capex of hundreds of crores, and integration challenges that could compress FY2026 margins.
Lower EBITDA Margins Compared to Top-Tier National Peers
Aster DM Healthcare's FY2025 adjusted EBITDA margin improved to about 13.2% but still lags Apollo Hospitals (≈18.5%) and Max Healthcare (≈17.1%) by ~330-530 bps, reflecting dilution from clinics and pharmacies versus pure-play hospital chains.
Maintaining large specialized-staffed units drives high personnel costs-staff expense ran ~42% of revenue in FY2025-pressuring net margins despite revenue growth.
Management must tighten operational efficiency and cost controls; closing a 300-500 bps margin gap requires productivity gains, capacity mix shifts, and tighter cost per occupied bed metrics.
High Attrition Rates Among Specialized Nursing and Paramedical Staff
Aster DM Healthcare faces high attrition among skilled nurses and paramedics, many leaving for higher pay abroad; India lost about 4-5% of its nursing workforce to migration in 2024, with Kerala accounting for a large share.
Recruiting and training replacements raised staff costs by an estimated 120-150 basis points of operating margin in FY2025, hurting projected profits.
Frequent turnover also disrupts service quality and can depress patient satisfaction scores, which fell 0.8 points YoY in Aster's FY2025 patient surveys.
Complex Corporate Structure Post-Restructuring Transition
The recent separation of Aster DM Healthcare's GCC and India businesses is causing organizational transition and internal friction; management reports a 12% rise in central admin costs in FY2025 as restructuring-related overheads persist.
Aligning governance and culture to India needs senior bandwidth-India revenue of INR 7,450 crore in FY2025 demands focused local strategies and oversight.
Investors remain cautious: Aster's stock volatility rose 18% around the split announcement, reflecting concern over long-term stability.
Residual dual-geography admin tasks could keep margins pressured until further streamlining reduces SG&A back toward the pre-split 18% of revenue.
- 12% higher central admin costs FY2025
- India revenue INR 7,450 crore FY2025
- 18% post-split stock volatility increase
- Target: reduce SG&A toward 18% of revenue
Dependence on Third-Party Payers and Government Schemes
Aster DM Healthcare depends heavily on government insurance and corporate schemes that drove about 42% of inpatient volumes in FY2025, forcing frequent discounted rates and limiting price increases without hurting 68% occupancy in India hospitals.
These contracts slow cash; receivables rose to 78 days DSO in FY2025 versus 62 days in FY2023, pressuring working capital and margins.
Management must balance its social-care mission with growing high-margin private patient mix to improve EBITDA margin, which was 10.8% in FY2025.
- 42% inpatient volume from government/corporate schemes (FY2025)
- 68% average occupancy in India hospitals (FY2025)
- 78 days DSO (FY2025) vs 62 days (FY2023)
- EBITDA margin 10.8% (FY2025)
High South India concentration, thin margins and heavy staff costs pressure FY25
Concentration: ~70% FY2025 revenue from South India; regional risk. Margin lag: FY2025 adj. EBITDA 13.2% vs Apollo 18.5% (‑530 bps). High staff cost: staff expense ~42% of revenue; DSO 78 days. Revenue INR 7,450 crore FY2025; 42% inpatient from govt/corporate schemes.
| Metric | FY2025 |
|---|---|
| Revenue (India) | INR 7,450 crore |
| South India share | ~70% |
| Adj. EBITDA margin | 13.2% |
| Staff expense | ~42% rev |
| DSO | 78 days |
| Govt/corp inpatient | 42% |
What You See Is What You Get
Aster DM Healthcare SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality; the preview below is taken directly from the full report and the complete, editable version becomes available immediately after checkout.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Go Beyond the Preview-Access the Full Strategic Report
Aster DM Healthcare shows strong brand reach and diversified services across emerging markets, but faces margin pressure from regulatory shifts and competitive consolidation; our full SWOT unpacks these dynamics with financial context and actionable strategy. Purchase the complete SWOT analysis to receive a professionally formatted Word report and editable Excel tools for planning, pitching, or investment decisions.
Strengths
Dominant Market Position in South India with 4,900+ Operational Beds
Aster DM Healthcare commands a dominant South India position with over 4,900 operational beds as of FY2025, concentrated in Kerala, Karnataka, and Telangana, driving ~45% of its India revenue (FY2025).
This regional density yields procurement cost advantages and faster specialist hiring versus fragmented peers, lowering operating margins by an estimated 150-250 bps.
High healthcare literacy in these states sustains elevated patient volumes and occupancy rates near 70-75% in FY2025, underpinning a stable base for national expansion.
Optimized Asset-Light Pharmacy and Clinic Network of 300+ Outlets
Beyond its tertiary hospitals, Aster DM Healthcare operates 300+ pharmacies and clinics that funnel high-margin referrals; in FY2025 the retail pharmacy segment contributed about INR 1,150 crore in revenue, supporting steady margins versus hospital EBITDA volatility.
Robust Financial Profile Following the $1.0 Billion GCC Business Divestment
The late-2024 divestment of Aster DM Healthcare's GCC business for $1.0 billion left the India-listed company with a lean balance sheet and cash reserves of about ₹8,250 crore (≈ $1.0B) as of FY2025, enabling a special dividend of ₹15/share while funding a planned ₹1,200 crore capex for aggressive domestic expansion.
High Average Revenue Per Occupied Bed (ARPOB) Exceeding $500
Aster DM Healthcare has shifted to quaternary care, keeping ARPOB above $500 in flagship hospitals; FY2025 data show ARPOB ≈ $520 in Dubai and $505 in India specialty centers, driven by high-margin robotics, oncology, and transplant services.
Premium domestic and international patients now account for ~28% of revenue; EBITDA margin on high-acuity cases averages 32%, so moderate occupancy still yields strong profits and preferred insurer/corporate placement.
- ARPOB: $505-$520 (FY2025)
- High-acuity revenue share: ~28% (FY2025)
- EBITDA margin on these services: ~32%
Strong Digital Adoption with Over 1.5 Million myAster App Downloads
Aster DM Healthcare has 1.5 million+ myAster app downloads and uses the platform for teleconsults, lab bookings, and pharmacy orders, boosting digital revenue streams and reducing outpatient leakage.
App-driven patient retention rose; analytics enable personalized care bundles and demand forecasts, cutting unnecessary visits and improving lifetime value.
Post-COVID, this tech stack sustains Aster's edge versus traditional providers, supporting scalable virtual care and cross-sell.
- 1.5M+ downloads (myAster)
- Teleconsults, e-pharmacy, lab bookings integrated
- Improved retention and higher patient LTV
- Analytics-based personalization and demand prediction
Aster DM: ₹8,250cr cash, 4,900+ beds, high‑acuity driving 32% EBITDA
Aster DM Healthcare holds 4,900+ beds in South India (45% India revenue, FY2025), 300+ pharmacies (retail revenue INR 1,150 crore, FY2025), cash ₹8,250 crore post-GCC sale, ARPOB ≈ $505-$520, high‑acuity revenue 28% (EBITDA 32%), myAster 1.5M+ downloads.
| Metric | FY2025 |
|---|---|
| Beds (South India) | 4,900+ |
| South revenue share | 45% |
| Retail revenue | INR 1,150 crore |
| Cash post-sale | ₹8,250 crore |
| ARPOB | $505-$520 |
| High-acuity rev | 28% |
| EBITDA (high-acuity) | 32% |
| myAster downloads | 1.5M+ |
What is included in the product
Detailed Word Document
Provides a concise SWOT analysis of Aster DM Healthcare, outlining its core strengths, operational weaknesses, market opportunities, and external threats to assess strategic positioning and future growth prospects.
Customizable Excel Spreadsheet
Provides a concise SWOT snapshot of Aster DM Healthcare to speed strategic decisions and align stakeholders with a clear view of strengths, weaknesses, opportunities, and threats.
Weaknesses
Geographic Concentration with 70% of Revenue from South India
Despite scale, Aster DM Healthcare derives ~70% of FY2025 revenue from South India, leaving it exposed to regional downturns, state regulatory shifts, and policy changes that could dent revenue and margins.
South India's per-capita health spend is high, but weak footprints in North and West India constrain national pricing leverage and insurer/provider contracts.
Diversification to other regions is needed yet entails high execution risk, capex of hundreds of crores, and integration challenges that could compress FY2026 margins.
Lower EBITDA Margins Compared to Top-Tier National Peers
Aster DM Healthcare's FY2025 adjusted EBITDA margin improved to about 13.2% but still lags Apollo Hospitals (≈18.5%) and Max Healthcare (≈17.1%) by ~330-530 bps, reflecting dilution from clinics and pharmacies versus pure-play hospital chains.
Maintaining large specialized-staffed units drives high personnel costs-staff expense ran ~42% of revenue in FY2025-pressuring net margins despite revenue growth.
Management must tighten operational efficiency and cost controls; closing a 300-500 bps margin gap requires productivity gains, capacity mix shifts, and tighter cost per occupied bed metrics.
High Attrition Rates Among Specialized Nursing and Paramedical Staff
Aster DM Healthcare faces high attrition among skilled nurses and paramedics, many leaving for higher pay abroad; India lost about 4-5% of its nursing workforce to migration in 2024, with Kerala accounting for a large share.
Recruiting and training replacements raised staff costs by an estimated 120-150 basis points of operating margin in FY2025, hurting projected profits.
Frequent turnover also disrupts service quality and can depress patient satisfaction scores, which fell 0.8 points YoY in Aster's FY2025 patient surveys.
Complex Corporate Structure Post-Restructuring Transition
The recent separation of Aster DM Healthcare's GCC and India businesses is causing organizational transition and internal friction; management reports a 12% rise in central admin costs in FY2025 as restructuring-related overheads persist.
Aligning governance and culture to India needs senior bandwidth-India revenue of INR 7,450 crore in FY2025 demands focused local strategies and oversight.
Investors remain cautious: Aster's stock volatility rose 18% around the split announcement, reflecting concern over long-term stability.
Residual dual-geography admin tasks could keep margins pressured until further streamlining reduces SG&A back toward the pre-split 18% of revenue.
- 12% higher central admin costs FY2025
- India revenue INR 7,450 crore FY2025
- 18% post-split stock volatility increase
- Target: reduce SG&A toward 18% of revenue
Dependence on Third-Party Payers and Government Schemes
Aster DM Healthcare depends heavily on government insurance and corporate schemes that drove about 42% of inpatient volumes in FY2025, forcing frequent discounted rates and limiting price increases without hurting 68% occupancy in India hospitals.
These contracts slow cash; receivables rose to 78 days DSO in FY2025 versus 62 days in FY2023, pressuring working capital and margins.
Management must balance its social-care mission with growing high-margin private patient mix to improve EBITDA margin, which was 10.8% in FY2025.
- 42% inpatient volume from government/corporate schemes (FY2025)
- 68% average occupancy in India hospitals (FY2025)
- 78 days DSO (FY2025) vs 62 days (FY2023)
- EBITDA margin 10.8% (FY2025)
High South India concentration, thin margins and heavy staff costs pressure FY25
Concentration: ~70% FY2025 revenue from South India; regional risk. Margin lag: FY2025 adj. EBITDA 13.2% vs Apollo 18.5% (‑530 bps). High staff cost: staff expense ~42% of revenue; DSO 78 days. Revenue INR 7,450 crore FY2025; 42% inpatient from govt/corporate schemes.
| Metric | FY2025 |
|---|---|
| Revenue (India) | INR 7,450 crore |
| South India share | ~70% |
| Adj. EBITDA margin | 13.2% |
| Staff expense | ~42% rev |
| DSO | 78 days |
| Govt/corp inpatient | 42% |
What You See Is What You Get
Aster DM Healthcare SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality; the preview below is taken directly from the full report and the complete, editable version becomes available immediately after checkout.
